Other
Standard chemoradiotherapy
Standard chemoradiotherapy is an intervention with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
COMBINATION PRODUCT
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed133%
unknown267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT03481114
unknownphase_3
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT02031939
unknownphase_3
Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage
NCT03403829
Clinical Trials (3)
Showing 3 of 3 trials
NCT03481114Phase 2
Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT02031939Phase 3
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT03403829Phase 3
Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage
All 3 trials loaded
Drug Details
- Intervention Type
- COMBINATION PRODUCT
- Total Trials
- 3